GORE-TEX PROPATEN Vascular Graft Study
This study has been completed.
Sponsor:
W.L.Gore & Associates
Information provided by:
W.L.Gore & Associates
ClinicalTrials.gov Identifier:
NCT00205790
First received: September 12, 2005
Last updated: August 6, 2008
Last verified: August 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To demonstrate equivalence in patency performance of GORE-TEX PROPATEN Vascular Grafts and Thin Walled GORE-TEX Stretch Vascular Grafts in a peripheral bypass application to support a claim of substantial equivalence.
| Condition | Intervention |
|---|---|
|
Peripheral Vascular Diseases |
Device: Vascular graft |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Treatment |
| Official Title: | Comparison of Primary Patency Between GORE-TEX PROPATEN Vascular Grafts and Thin Walled GORE-TEX Stretch Vascular Grafts |
Resource links provided by NLM:
Further study details as provided by W.L.Gore & Associates:
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient requires primary above-knee bypass where the proximal anastomosis will be to the common femoral or proximal superficial femoral artery and the distal anastomosis will be the popliteal artery proximal to the medial head of the gastrocnemius;
- Patient has Grade III or IV occlusive vascular disease;
- Patient has a postoperative life expectancy greater than one year;
- Patient is at least 21 years of age;
- Patient is able to comply with all study requirements and be available for follow-up visits at 1 month, 6 months and 12 months post procedure;
- Patient is willing and able to provide written, informed consent.
Exclusion Criteria:
- Patient had a previous bypass in the diseased extremity (below iliacs);
- Patient has known coagulation disorders including hypercoagulability;
- Patient has had any previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or has known hypersensitivity to heparin;
- Patient has an acute embolic arterial occlusion;
- Patient requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts;
- Patient had percutaneous transluminal angioplasty to the implant site within the previous 30 days;
- Patient is in need of, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure;
- Patient has active infection in the region of graft placement; or
- Patient has an incomplete preoperative assessment (as outlined in this protocol) due to an emergency procedure, a traumatic injury or any other reason.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00205790
Locations
| United States, District of Columbia | |
| Georgetown University Hospital | |
| Washington, District of Columbia, United States, 20007 | |
| United States, Florida | |
| Memorial Regional Hospital | |
| Hollywood, Florida, United States, 33028 | |
| St. Vincent's Hospital | |
| Jacksonville, Florida, United States, 32204 | |
| Sacred Heart Hospital | |
| Pensacola, Florida, United States, 32504 | |
| United States, Georgia | |
| Medical Center of Central Georgia | |
| Macon, Georgia, United States, 31201 | |
| United States, Kentucky | |
| Jewish Hospital | |
| Louisville, Kentucky, United States, 40202 | |
| United States, Maryland | |
| Upper Chesapeake Medical Center | |
| Baltimore, Maryland, United States, 21014 | |
| United States, Massachusetts | |
| Baystate Medical Center | |
| Springfield, Massachusetts, United States, 01107 | |
| Mercy Medical Center | |
| Springfield, Massachusetts, United States, 01107 | |
| United States, Michigan | |
| William Beaumont Hospital | |
| Bingham Farms, Michigan, United States, 48025 | |
| Borgess Hospital | |
| Kalamazoo, Michigan, United States, 49048 | |
| United States, Mississippi | |
| University of Mississippi Medical Center | |
| Jackson, Mississippi, United States, 39216 | |
| United States, New Jersey | |
| Morristown Memorial Hospital | |
| Morristown, New Jersey, United States, 07960 | |
| United States, New York | |
| Maimonides Hospital | |
| Brooklyn, New York, United States, 11219 | |
| United States, Ohio | |
| Ohio State University Medical Center | |
| Columbus, Ohio, United States, 43210 | |
| United States, Pennsylvania | |
| Wilkes-Barre General Hospital | |
| Plains, Pennsylvania, United States, 18705 | |
| United States, Tennessee | |
| Baptist East Hospital | |
| Memphis, Tennessee, United States, 38120 | |
| United States, West Virginia | |
| Charleston Area Medical Center | |
| Charleston, West Virginia, United States, 25304 | |
Sponsors and Collaborators
W.L.Gore & Associates
Investigators
| Principal Investigator: | Enrico Ascher, MD | Maimonides Hospital, Brooklyn NY |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00205790 History of Changes |
| Other Study ID Numbers: | PPT-01-04 |
| Study First Received: | September 12, 2005 |
| Last Updated: | August 6, 2008 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Vascular Diseases Peripheral Vascular Diseases Peripheral Arterial Disease Cardiovascular Diseases |
Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases |
ClinicalTrials.gov processed this record on May 16, 2013